Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges

References

• Chaigne B, Watier H. Theranostic of biopharmaceuticals. P Pharmacol Ther 2017 Feb 13. pii: S0163-7258(17)30049-9. PMID:28223229; https://doi.org/10.1016/j.pharmthera.2017.02.035
   PubMed Web of Science ®Google Scholar
• Pèlegrin A, Daguet A, Watier H. MAbImprove: A French ‘Laboratoire d'excellence’ (LabEx) dedicated to therapeutic antibodies. mAbs 2014; 6(4):803-4; PMID:24842678; https://doi.org/10.4161/mabs.29262
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Marketing approval of mogamulizumab: A triumph for glyco-engineering. MAbs 2012; 4(4):419-25; PMID:22699226; https://doi.org/10.4161/mabs.20996
   PubMed Web of Science ®Google Scholar
• Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: First global approval. Drugs 2012; 72(9):1293-8; PMID:22686619; https://doi.org/10.2165/11631090-000000000-00000
   PubMed Web of Science ®Google Scholar
• Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2010; 2(6):594-606; PMID:20864805; https://doi.org/10.4161/mabs.2.6.13420
   PubMed Web of Science ®Google Scholar
• Errey JC, Doré AS, Zhukov A, Marshall FH, Cooke RM. Purification of Stabilized GPCRs for Structural and Biophysical Analyses. Methods Mol Biol Clifton NJ 2015; 1335:1-15; PMID:26260590; https://doi.org/10.1007/978-1-4939-2914-6_1
   PubMedGoogle Scholar
• Kean J, Bortolato A, Hollenstein K, Marshall FH, Jazayeri A. Conformational thermostabilisation of corticotropin releasing factor receptor 1. Sci. Rep 2015; 5:11954; PMID:26159865; https://doi.org/10.1038/srep11954
   PubMed Web of Science ®Google Scholar
• Hollenstein K, Kean J, Bortolato A, Cheng RK, Doré AS, Jazayeri A, Cooke RM, Weir M, Marshall FH. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 2013; 499(7459):438-43; PMID:23863939; https://doi.org/10.1038/nature12357
   PubMed Web of Science ®Google Scholar
• Cooke RM, Koglin M, Errey JC, Marshall FH. Preparation of purified GPCRs for structural studies. Biochem Soc Trans 2013; 41(1):185-90; PMID:23356281; https://doi.org/10.1042/BST20120240
   PubMed Web of Science ®Google Scholar
• Slack RJ, Russell LJ, Barton NP, Weston C, Nalesso G, Thompson SA, Allen M, Chen YH, Barnes A, Hodgson ST, et al. Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor. Pharmacol Res Perspect 2013; 1(2):e00019; PMID:25505571; https://doi.org/10.1002/prp2.19
   PubMedGoogle Scholar
• Jazayeri A, Marshall F. Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics. Expert Rev Neurother 2015; 15(2):123-5; PMID:25578566; https://doi.org/10.1586/14737175.2015.1001369
   PubMed Web of Science ®Google Scholar
• Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011; 477(7366):549-55; PMID:21772288; https://doi.org/10.1038/nature10361
   PubMed Web of Science ®Google Scholar
• Hutchings CJ, Cseke G, Osborne G, Woolard J, Zhukov A, Koglin M, Jazayeri A, Pandya-Pathak J, Langmead CJ, Hill SJ, et al. Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment. mAbs 2014; 6(1):246-261; PMID:24253107; https://doi.org/10.4161/mabs.27226
   PubMed Web of Science ®Google Scholar
• Rossant CJ, Carroll D, Huang L, Elvin J, Neal F, Walker E, Benschop JJ, Kim EE, Barry ST, Vaughan TJ. Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes. mAbs 2014; 6(6):1425-38; PMID:25484064; https://doi.org/10.4161/mabs.34376
   PubMed Web of Science ®Google Scholar
• Douthwaite JA, Sridharan S, Huntington C, Hammersley J, Marwood R, Hakulinen JK, Ek M, Sjögren T, Rider D, Privezentzev C, et al. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1. mAbs 2015; 7(1):152-166; PMID:25484051; https://doi.org/10.4161/19420862.2014.985158
   PubMed Web of Science ®Google Scholar
• Bourquard T, Landomiel F, Reiter E, Crépieux P, Ritchie DW, Azé J, Poupon A. Unraveling the molecular architecture of a G protein-coupled receptor/β-arrestin/Erk module complex. Sci Rep 2015; 5:10760; PMID:26030356; https://doi.org/10.1038/srep10760
   PubMed Web of Science ®Google Scholar
• Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U A 2010; 107:20565-70; PMID:21059953; https://doi.org/10.1073/pnas.1012865107
   PubMed Web of Science ®Google Scholar
• Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, Leurs R. Pharmacological modulation of chemokine receptor function. Br J Pharmacol 2012; 165:1617-43; PMID:21699506; https://doi.org/10.1111/j.1476-5381.2011.01551.x
   PubMed Web of Science ®Google Scholar
• Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, et al. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem 2013; 288:29562-72; PMID:23979133; https://doi.org/10.1074/jbc.M113.498436
   PubMed Web of Science ®Google Scholar
• Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, De Taeye S, Van den Heede K, Roobrouck A, Grot E, Kent TC, et al. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. Mol Pharmacol 2015; 87:251-262; PMID:25468882; https://doi.org/10.1124/mol.114.094821
   PubMed Web of Science ®Google Scholar
• Mujić-Delić A, de Wit RH, Verkaar F, Smit MJ. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics. Trends Pharmacol Sci 2014; 35(5):247-55; PMID:24690241; https://doi.org/10.1016/j.tips.2014.03.003
   PubMed Web of Science ®Google Scholar
• Rondard P, Pin JP. Dynamics and modulation of metabotropic glutamate receptors. Curr Opin Pharmacol 2015; 20:95-101; PMID:25529199; https://doi.org/10.1016/j.coph.2014.12.001
   PubMed Web of Science ®Google Scholar
• Claes K, Vandewalle K, Laukens B, Laeremans T, Vosters O, Langer I, Parmentier M, Steyaert J, Callewaert N. Modular integrated secretory system engineering in Pichia pastoris To enhance G-Protein coupled receptor expression. ACS Synth Biol 2016; 5:1070-5; PMID:27176489; https://doi.org/10.1021/acssynbio.6b00032
   PubMed Web of Science ®Google Scholar
• Peyrassol X, Laeremans T, Gouwy M, Lahura V, Debulpaep M, Van Damme J, Steyaert J, Parmentier M, Langer I. Development by genetic immunization of monovalent antibodies (Nanobodies) behaving as antagonists of the human ChemR23 receptor. J Immunol 2016; 196:2893-901; PMID:26864035; https://doi.org/10.4049/jimmunol.1500888
   PubMed Web of Science ®Google Scholar